CA2521891A1 - Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) - Google Patents

Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) Download PDF

Info

Publication number
CA2521891A1
CA2521891A1 CA002521891A CA2521891A CA2521891A1 CA 2521891 A1 CA2521891 A1 CA 2521891A1 CA 002521891 A CA002521891 A CA 002521891A CA 2521891 A CA2521891 A CA 2521891A CA 2521891 A1 CA2521891 A1 CA 2521891A1
Authority
CA
Canada
Prior art keywords
phenylamino
methylethyl
fluorophenyl
pyrrole
dihydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002521891A
Other languages
French (fr)
Other versions
CA2521891C (en
Inventor
Stephen Robert Byrn
David Andrew Coates
Karen Sue Gushurst
Henry Grant Ii Morrison
Aeri Park
Petinka Ivanova Vlahova
Zheng Jane Li
Joseph Francis Krzyzaniak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35452260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2521891(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority claimed from CA002450111A external-priority patent/CA2450111C/en
Publication of CA2521891A1 publication Critical patent/CA2521891A1/en
Application granted granted Critical
Publication of CA2521891C publication Critical patent/CA2521891C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-.beta., .DELTA.4;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt atorvastatin designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.
CA002521891A 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) Expired - Fee Related CA2521891C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30204901P 2001-06-29 2001-06-29
US60/302,049 2001-06-29
CA002450111A CA2450111C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002450111A Division CA2450111C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)

Publications (2)

Publication Number Publication Date
CA2521891A1 true CA2521891A1 (en) 2003-01-16
CA2521891C CA2521891C (en) 2006-04-25

Family

ID=35452260

Family Applications (14)

Application Number Title Priority Date Filing Date
CA002521891A Expired - Fee Related CA2521891C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
CA002522899A Expired - Fee Related CA2522899C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
CA002521953A Expired - Fee Related CA2521953C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA002521908A Expired - Fee Related CA2521908C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
CA002521958A Expired - Fee Related CA2521958C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-pheyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA002521792A Expired - Fee Related CA2521792C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
CA002521933A Expired - Fee Related CA2521933C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
CA002521993A Abandoned CA2521993A1 (en) 2001-06-29 2002-05-21 Crystalline forms of ¬r-(r*,r*)|-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-¬(phenylamino)carbonyl|-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA002521980A Expired - Fee Related CA2521980C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA002521828A Expired - Fee Related CA2521828C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA002521776A Expired - Fee Related CA2521776C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
CA002521956A Expired - Fee Related CA2521956C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA002521833A Expired - Fee Related CA2521833C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA002521887A Expired - Fee Related CA2521887C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)

Family Applications After (13)

Application Number Title Priority Date Filing Date
CA002522899A Expired - Fee Related CA2522899C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
CA002521953A Expired - Fee Related CA2521953C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA002521908A Expired - Fee Related CA2521908C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
CA002521958A Expired - Fee Related CA2521958C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-pheyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA002521792A Expired - Fee Related CA2521792C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
CA002521933A Expired - Fee Related CA2521933C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
CA002521993A Abandoned CA2521993A1 (en) 2001-06-29 2002-05-21 Crystalline forms of ¬r-(r*,r*)|-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-¬(phenylamino)carbonyl|-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA002521980A Expired - Fee Related CA2521980C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA002521828A Expired - Fee Related CA2521828C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA002521776A Expired - Fee Related CA2521776C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
CA002521956A Expired - Fee Related CA2521956C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA002521833A Expired - Fee Related CA2521833C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA002521887A Expired - Fee Related CA2521887C (en) 2001-06-29 2002-05-21 Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)

Country Status (1)

Country Link
CA (14) CA2521891C (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610344A2 (en) 2005-12-13 2016-11-29 Teva Pharma crystallized form of atorvastatin hemi-calcium, process for its preparation, derived pharmaceutical product and its medicinal use

Also Published As

Publication number Publication date
CA2521833A1 (en) 2003-01-16
CA2521887A1 (en) 2003-01-16
CA2521980A1 (en) 2003-01-16
CA2521828A1 (en) 2003-01-16
CA2521993A1 (en) 2003-01-16
CA2521956C (en) 2006-04-25
CA2521953C (en) 2006-03-14
CA2521958C (en) 2006-08-29
CA2521887C (en) 2006-04-25
CA2521953A1 (en) 2003-01-16
CA2521776A1 (en) 2003-01-16
CA2521908A1 (en) 2003-01-16
CA2522899A1 (en) 2003-01-16
CA2521891C (en) 2006-04-25
CA2521792A1 (en) 2003-01-16
CA2521908C (en) 2006-04-25
CA2521956A1 (en) 2003-01-16
CA2522899C (en) 2006-04-25
CA2521776C (en) 2006-04-25
CA2521980C (en) 2006-08-29
CA2521933C (en) 2006-03-21
CA2521828C (en) 2006-04-25
CA2521833C (en) 2006-04-25
CA2521933A1 (en) 2003-01-16
CA2521792C (en) 2006-04-25
CA2521958A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
CA2450111A1 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
CA2220018A1 (en) Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
IL122162A0 (en) Crystalline form III atorvastatin and pharmceutical compositions containing it
EP2540704A3 (en) Benethamine salt forms of atorvastatin
CA2521887A1 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
TH61086A (en) Crystalline form of calcium salts (2

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190521